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DR. RAMIREZ
(1) Well, thank you for joining us today for another
session of COVID-19 Research Conversations, and to-
day the conversation is going to be with two friends
from New York City. I want to ask Mike and Ed to in-
troduce themselves, and then we’ll begin the presenta-
tion. Mike?
DR. NIEDERMAN
(2) Well, thank you, Julio. It’s really a pleasure to be
able to do this. My name is Mike Niederman; I’m a Pul-
monary Critical Care specialist at Weill Cornell Medical
College and New York Presbyterian Weill Cornell Med-
ical Center in New York City. I’m the Clinical Director
and Associate Chief in the Division of Pulmonary and
Critical Care. And with me is one of our star intensive
care colleagues, Ed Schenck; I’ll let him introduce him-
self in a moment. I’ve been involved in a number of
different activities throughout COVID, some adminis-
trative, some clinical, more outpatient than inpatient,
some inpatient work in the ICU, some video work in
the ICU, and again, all the outpatient issues that we’re
going to talk about as well. And I’m very much in-
volved in discussing clinical trials and focusing more
recently on the problems of the patients who’ve had
COVID and are recovering. But I’d like to introduce Ed
Schenck, who’s been a key inpatient doctor, and partic-
ularly key in organizing our participation in a number
of clinical trials. Ed?
DR. SCHENCK
(3) Thanks, Mike; thanks, Julio. I’m Ed Schenck; I’m
an Assistant Professor of Clinical Medicine at Weill
Cornell. I’m a full time practicing intensivist/clinical
researcher, and I see the role of clinical research with
COVID-19 as the intersection between clinical trials,
data science and translational science. We tried at Cor-
nell in the spring surge to answer the call for inpatient
data about the pandemic, getting our intensive care
unit and our pulmonary service up and running with
as many clinical trials as possible, but also generating
data at the same time. And that happened through a
lot of the work at our institution and also internation-
ally. So, there’s a lot of interesting things to talk about.
Thanks very much.
DR. RAMIREZ
(4) Excellent. Just jump directly into lessons learned,
Mike.
DR. NIEDERMAN
(5) Great! Well, early on, as I’m sure you remem-
ber, New York City was at the epicenter of COVID-
19. We saw very many patients—probably something
of the order of 1,300 patients—in the springtime, and
we have another surge going on now, but the numbers
are not quite as dramatic. Currently, we probably have
something like a quarter as many patients in the hos-
pital as we did in the Spring. Likewise, in the ICU, we
have fewer than in the Springtime, and interestingly,
fewer patients are mechanically ventilated in this cur-
rent surge. Early on, I worked with one of our other
faculty members, Meredith, to summarize our experi-
ence treating COVID. We took the possibly provocative
stance that what we learned about how to manage pa-
tients in our specialty of pulmonary critical care during
this time will have long-lasting and, I would argue, per-
manent changes on the practice of our specialty. Once
COVID is long gone, many of the things we’ve learned
will serve us well going forward, and there will be im-
portant changes in how we practice.
(6) In this article, we summarize the changes in out-
patient care, inpatient care, and medical education.[1] I
don’t want to go through everything exhaustively here,
but I want to touch on a couple of things. In outpa-
tient practice, we have of course, as I’m sure all of you
have, had to rely extensively on telemedicine; I think
that will continue going forward. I think we were re-
luctant to do telemedicine in ways that we’re currently
doing it. We’ve become much more comfortable, we’re
doing a lot more, and we’re following patients closer
than we thought we could with telemedicine. And I
think that for some patients, it gives them access to care
that they didn’t have before. One of the things that we
were worrying about then and still worry about is that
patients are so scared to come out and go to the office,
or so frightened by the technology of telemedicine that
they don’t contact the doctor. And we’re worried that
some of our patients with serious respiratory problems
might neglect those problems and not manage them
completely effectively because of the concerns that are
generated by COVID. There are multiple long-term se-
quelae, which I think are going to dominate our out-
patient practice of pulmonary medicine—again, long
after COVID is gone. We’ve seen patients with unex-
plained dyspnea that we can’t really account for phys-
iologically; cough has been a very prominent symp-
tom that’s persisted in some patients for months and
months, and although some of that may represent bron-
chospasm, we don’t understand all the factors that con-
tribute to cough; we’ve seen persistent lung infiltrates
that can lead to fibrosis, organizing pneumonia, and
persistent need for oxygen even in the absence of some
of the lung infiltrates. And we’ve established a post–
COVID-ICU multidisciplinary care program. We had
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a fledgling post-ICU clinic before COVID, but that’s
been ramped up dramatically because of all the sur-
vivors that we’ve had from the ICU and all their ongo-
ing needs. And this clearly has to be a multidisciplinary
effort.
(7) These are some of the things that we’ve had to
deal with, but again, I think we will continue to deal
with them. The problems after COVID are well docu-
mented in many studies. In this particular study, for
example, nearly 90% of patients who were hospital-
ized in Italy had at least one persistent symptom two
months or longer after initial onset.[2] We also know
that the severity of the COVID doesn’t necessarily cor-
relate with the persistence of symptoms. Patients who
have symptoms persisting may have had mild COVID,
and people with more severe COVID may be debili-
tated but may not have some of the same persistent
symptoms. In addition to respiratory symptoms, they
can have fatigue, chest pain, cardiac arrhythmias, and
we’re learning about the multi-system nature of the se-
quelae of COVID. In our hospital, one of our patholo-
gists has done a very interesting multi-center autopsy
study; they demonstrated that 84% of patients at au-
topsy had a tracheobronchitis, and there were virus el-
ements in the airway epithelium and type II pneumo-
cytes.[3] In this picture from the autopsy (Figure 1), you
can see an ulcerated lesion in the trachea. Our clini-
cal impression from people who’ve survived COVID is
that many of them have persistent airway symptoms.
We see that in the office after they’ve left the hospital;
they have persistent coughing, and some respond to
bronchodilators, and sometimes corticosteroids treat-
ment as if it’s bronchospasm. But nowadays, it’s much
more refractory. And I think we’re going to learn more
about the mechanisms of cough in general, but partic-
ularly the cough related to COVID.
(8) On the inpatient side, at the peak of the pandemic
in the Spring, we had about 250 patients in ICU. Our
hospital is built with an ICU capacity of about 110–120.
So, to accommodate those numbers in the ICUs, we had
to redefine what an ICU is; we took the elements of the
ICU and put them in places that were not traditional
ICU settings. We worked very hard to establish mul-
tidisciplinary teams with different care responsibilities.
For example, anesthesiologists were not doing elective
surgery at the time, so they were available to help us
as part of an intubation team. Physical therapists were
helping us proning patients who needed prone ventila-
tion as treatment for ARDS. And we had other people
from different disciplines—neurology, critical care, car-
diac critical care, and surgical critical care—working,
again, to be part of a multidisciplinary ICU team. We
also had some of the surgical interventionalists help us
as a line placement team. But we also didn’t have an
exclusively medical or exclusively surgical ICU team
taking care of these patients; we mixed a number of dis-
ciplines, and we included hospitalists as well.
(9) There are new approaches to treatment of ARDS
that I’m going to let Ed talk about. We used, of course,
non-invasive ventilation and high-flow nasal cannula. I
think we’ve become more comfortable with using that
as a way of treating patients and delaying intubation;
early on, we were more reluctant to do that than we are
now. We’ve certainly focused on multi-system organ
failure. And I think that all of this has reinforced to us
the importance of viral causes of community-acquired
pneumonia. I’ll refer you to this article, which some
of our colleagues wrote in the American Journal of Res-
piratory and Critical Care Medicine, talking about ways
that we developed to deal with ICU needs in a non-
traditional fashion.[4] I think that fast-file response will
probably continue as we go forward. I’m going to let
Ed talk a little bit more about ventilation, but this is
a phenomenal paper that he was part of.[5] And the
far right column here (Table 1) looks at the respiratory
mechanics and respiratory support in 270 patients with
respiratory failure and COVID that were treated in our
hospital. And I think I’ll just lay the groundwork for
some of the therapies, but I like this paradigm of break-
ing COVID down into different phases. When we look
at treatments that we consider good in the early stage
versus the late stage, in mild disease versus severe dis-
ease, I think we also have to look at those phases as re-
lating to the events that are happening—meaning that
early on, in milder disease, there’s a predominance of
viral illness that’s making the patient sick, and as that
viral illness begins to fade away and is replaced by an
inflammatory response, that’s the factor that’s making
patients sick. So it stands to reason from that patho-
genesis that antiviral therapies, which include, for ex-
ample, monoclonal antibodies and convalescent serum
antibodies, are going to be most effective early in the
disease with milder illness when the virus is predomi-
nating. And in later phases of the disease, when the pa-
tients are sicker, and when they have inflammation pre-
dominating, an anti-inflammatory therapy makes the
most sense.
(10) We again reinforced all the basic principles of
critical care in the treatment of ARDS: mechani-
cal ventilation, non-invasive ventilation, high flow
and, of course, the importance of negative pressure
ventilation, and some of the prophylaxis that we
need to do and thinking about complications like
ventilator-associated pneumonia, venous thromboem-
bolism, catheter-related bloodstream infections, stress,
GI bleeding, and other issues. So now, I’m going to turn
the podium, if you will, back to Ed, and I’ll let him talk
about what he’s learned, particularly about the inpa-
tient and ICU management of these patients, because
he’s been involved in some phenomenal studies that
have helped elucidate principles in critical care that we
now understand better, and I think will form the basis,
as I mentioned earlier, of changing our practice going
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Figure 1. Tracheobronchial inflammation in COVID-19: a, b are gross photographs of trachea and main stem bronchus showing circumscribed
white patches of 2.0–3.0 mm in diameter. c Microscopy of these lesions show ulceration with acute and chronic inflammation, d some with
associated necrosis and fibrin. (a, b Gross photograph, Hematoxylin and eosin stain, c x50 and d x100.)
Reprinted by permission from Macmillan Publishers Ltd: Modern Pathology (Borczuk AC, Salvatore SP, Seshan S V, et al. COVID-19
pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol 2020; 33:2156–2168. Available at:
https://www.nature.com/articles/s41379-020-00661-1), copyright 2020.
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Table 1. Respiratory mechanics and respiratory support in 267 patients with respiratory failure and COVID-19 treated in a New York hospital.[5]
New York City, NY, USA
Respiratory Support∗
Invasive mechanical ventilation 267 (100%)
Non-invasive ventilation 51 (19%)
High-flow nasal cannula 0
PaO2/FiO2 ratio 103 (82–134)
Compliance, mL/cm H2O 28 (23–38)
Plateau pressure, cm H2O 25 (21–29)
Positive end-expiratory pressure, cm H2O 10 (8–12)
Tidal volume, mL/kg PBW 7.0 (6.1–8.1)
Prone positioning 108 (40%)
PaO2=partial pressure of arterial oxygen; FiO2=fraction of inspired oxygen; PBW=predicted bodyweight.
∗Some patients received more than one type of respiratory support.
forward.
DR. SCHENCK
(11) Thanks very much, Mike. I’m going to present
some of our observational data that we have been
putting together and some of what I think about re-
garding the natural history of critical illness in general
and with a focus on COVID. At Cornell, in the immedi-
ate first surge, the first priority for all of us as practic-
ing intensivists was scrambling to take care of this mas-
sive surge of patients with respiratory failure, and mak-
ing sure that the basics were done well. That means
getting people appropriate oxygen therapy, intubation,
and appropriate support when on the ventilator, and
then dealing with other organ failure supports as they
emerged, such as renal failure or cardiovascular failure.
And as that was happening, and as we extended our
capacity beyond our usual ICUs, it was really an ad-
ministrative tour de force from the top of our institution
through our practicing doctors coordinating expansion
of ICU care beyond our regular ICU walls. There were
redundancies in terms of who was caring for patients,
and also which patients would be best served in which
environment. We had a kind of hub-and-spoke mental-
ity in terms of where patients were initially resuscitated
and then moved into other types of care locations after
the initial resuscitation period.
(12) So there were tiers of critical illness in terms of
how patients would be distributed, and some of that
will never make it into an actual journal because it was
kind of difficult to define, but it was potentially life-
saving for a lot of patients who were moved from op-
erating rooms to main ICUs and out to pop-up ICUs,
and it was really marvelous to see. So, clinical care was
the top priority, but at the same time, we wanted to
generate treatments and data and get involved in clini-
cal trials, because the treatment of this disease had so
many unknowns. I served on our medical college’s
steering committee, assigning priorities to our clinical
trials because there was competition among pharma-
ceutical companies and from NIH and other organi-
zations in terms of which trials would be entertained
and which would add value. So, in a very delib-
erative process, we really prioritized our own inter-
nal investigator-initiated studies to highlight our own
emerging talent, but also the large phase-three multi-
center studies that had good scientific rationale, much
as Mike outlined in terms of the antiviral phase, the
anti-inflammatory phase of the virus, and also the clin-
ical phases of the disease, from the outpatient to the
moderate inpatient disease to the severe or critical in-
patient disease, making sure that there were options for
patients within each phase of the disease and within
mechanistic classes, being antivirals, anti-thrombotic
agents, and anti-inflammatory. Really, thinking proac-
tively as an institution about filling up each one of
those buckets was really important. This observational
data is a combination of how we adapted our ICU re-
search infrastructure to the expanded ICU capability,
so we had to adapt how we collected and analyzed our
data.We also participated in several multicenter obser-
vational studies at the same time, providing data to
larger groups. So I’m going to get into my talk now.
So this is understanding the natural history of severe
COVID.
(13) The challenge with severe COVID-19, or any sort
of disease that requires organ failure support, is that the
disease process takes the form of an arc, and the job of
an intensivist to get patients through these sorts of dis-
ease is to support failing organs as the natural history
unfolds. And then, you also have anti-pathogen ther-
apy and anti-inflammatory responses that can make the
period of organ failure less severe—or make the dam-
age related to our organ failure–supportive therapies
less severe—so less ventilator-associated lung injury,
less delirium associated with sedatives, etc.—to get the
patients through to the other side of the natural history.
So, what we tried to do here at Cornell was to under-
stand the natural history of COVID-19 ARDS a little
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better. The challenge of understanding the natural his-
tory of severe critical illnesses is that patients don’t nec-
essarily all arrive at the ICU at the same point in their
clinical course, although it seems as though with severe
COVID, they usually arrive in a hyper-inflammatory
state, although not the traditional cytokine release syn-
drome that was defined earlier. In a stereotypical chest
X-ray of a COVID-19 patient with ARDS, with me-
chanical ventilation treatment, you see diffuse bilateral
patchy opacities in all lung fields. However, very early
on, doctors saw that not every patient actually fit this
bill in that not everyone had diffuse bilateral patchy
opacities, despite marked degrees of hypoxemia, so we
really wanted to understand the variability. This is part
of the understanding of the respiratory mechanics and
gas exchange.
(14) This paper that we published in the annals of the
American Thoracic Society was a research letter sum-
marizing our early experience with about 260 patients
requiring mechanical ventilation with severe COVID
during our “surge” experience.[6] We broke this down
by eventual mortality—we had an inpatient mortality
of about 30% of our mechanically ventilated patients—
versus eventual discharge, examining how a patient’s
mechanics on day 1 associated with the eventual out-
come. And you can see (Table 2) that the P -values
on the right are all greater than 0.05, so there were no
statistically significant difference between any of the
mechanical ventilation parameters that would predict
eventual outcomes; this includes the amount of ap-
plied PEEP, the minute ventilation, the PEEP pressures;
the plateau pressures were a little higher for patients
who were eventually deceased, the PF ratios were little
lower, and the compliance was a little lower, but none
of this was statistically significant.
(15) What we did see, though, is that plateau pressures
and minute volume exhaled slowly changed over time,
and patients who were eventually discharged have a
slight decrease in their trajectory, which the patients
who were eventually deceased never had. So, that got
us thinking about whether or not the trajectory of dis-
ease mattered more than upfront inflammatory burden
or upfront severity of disease. And the world now un-
derstands this, but early on in the pandemic, it was
shocking to understand how much non-pulmonary or-
gan failure there was with severe COVID-19. So these
are some of the collaborative efforts within Cornell. We
saw with our neurology colleagues that stroke was very
common, not only in the critically ill population, but
with our moderate patients as well. Myocardial infarc-
tion was very common, ARDS is extremely common,
thromboembolic events, as highlighted by our hospital-
ist colleagues, were incredibly common with COVID-
19, and renal failure, additionally, was very common.
(16) This is a paper from the STOP-COVID collabo-
ration, to which we contributed about 90 of our early
patients (there are about 8 publications so far from
this group based out of Brigham and Women’s.[7] The
idea here is that organ dysfunction beyond respira-
tory failure was one of the key associations with poor
outcomes. You can see1 that these are individual or-
gan failures—heart failure, liver injury, kidney injury,
shock—and that all of these by themselves are associ-
ated with different risks of mortality, but you can also
see that cumulative organ failure really has stepwise as-
sociation with risk. And so, with this cumulative organ
failure driving outcomes, it’s a kind of tautology, be-
cause the more organs that are shut down, the worse
you’re going to do. But we decided to look at this in
a different way using the SOFA scoring system to see
whether there were any sort of novel subphenotyping
mechanisms we could look at within our mechanically
ventilated population.
(17) This is a Sankey diagram,2 which is a little hard
to understand, but these are good SOFA scores at the
top in the white bar, with the darker bars representing
higher severity of illness. This is from a Blue Journal
paper from 2019 that looked at Andromeda Shock—cap
refill versus lactate clearance in terms of resuscitation
for sepsis—but the idea here is that over time, patients
move through different levels of organ dysfunction.[8]
An idea that I’ve been thinking about for a while is that
a patient beginning at a middling level of organ dys-
function could improve, stay the same, or worsen (and
the black bars represent death), so there are many dif-
ferent options for what happens as you move from state
to state, and this can be repeated at every state. So what
arc is the natural history of this type of organ dysfunc-
tion, and how many patients actually fit within these
progression pathways?
(18) So we did this with our COVID-19 population
in collaboration with our machine learning colleagues
and informatics group.[9] We looked at our COVID
population at the time of intubation, both at our pri-
mary institution at Weill Cornell and then repeated at
Lower Manhattan, and then bucketed this group in
terms of mild, intermediate, and severe baseline levels
of organ dysfunction. We then looked at trajectory sim-
ilarity through a technique called dynamic time warp-
ing, and then used hierarchical clustering after that in
order to see whether the trajectories grouped together.
So that means whether patients with differing levels
of baseline severity of illness move together through
that severity of illness in a similar fashion. What we
found is that the organ dysfunction was additive—mild
1See Gupta et al.[7] supplemental content eFigure 5. Acute Organ Injury (https://jamanetwork.com/journals/jamainternalmedicine/
fullarticle/2768602).
2See Zampieri et al.[8] Figure 2. Alluvial plot for SOFA category across time (https://www.atsjournals.org/doi/full/10.1164/rccm.201905-
0968OC).
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Table 2. Ventilator Parameters by Status, Day 1.[6]
Characteristic Deceased, N = 90 Discharged, N = 170 p-value q-value
PCO2 Arterial 46 (38, 52) 44 (38, 52) 0.5 0.8
PO2 Arterial 92 (75, 121) 93 (74, 130) >0.9 >0.9
Minute Volume Exhaled 9.80 (8.33, 11.80) 9.30 (8.15, 11.35) 0.4 0.7
PEEP 10.0 (9.0, 12.0) 10.0 (8.5, 12.0) 0.3 0.6
Tidal Volume 450 (400, 500) 450 (400, 500) 0.8 >0.9
Peak Inspiratory Pressure 31.0 (25.0, 35.0) 30.0 (26.0, 34.8) 0.6 0.8
Plateau Pressure 26.0 (22.0, 30.0) 24.5 (21.0, 28.0) 0.2 0.6
PF Ratio 105 (84, 137) 117 (86, 160) 0.086 0.5
Tidal Volume / PBW 6.92 (6.24, 7.70) 7.06 (6.36, 8.31) 0.2 0.6
Static Compliance 28 (23, 36) 29 (22, 40) 0.4 0.7
Driving Pressure 15.0 (12.0, 18.2) 14.0 (11.0, 16.5) 0.065 0.5
Ventilatory Ratio 1.93 (1.51, 2.32) 1.80 (1.47, 2.30) 0.6 0.8
severity of illness was respiratory failure and neuro-
logic dysfunction; intermediate severity of illness was
additive cardiovascular dysfunction; and most severe
was additive renal failure. We did not see almost any
upfront liver failure or upfront coagulopathy in the se-
vere COVID patients, and we did not see kidney failure
without cardiovascular failure.
(19) There were only 2 defined trajectories within each
organ dysfunction baseline category, a very simple
“worsening” or “improving.” So the red line (Figure 2)
is the worsening group—over time, the patients them-
selves had a SOFA trajectory that was increasing. The
blue line is the improving group, whose SOFA values
were decreasing. And this repeated within each bucket
of mild, intermediate, and severe. And we saw that
if the SOFA scores of the mild group were worsening
(red line, Figure 3), their outcomes were actually worse
than those of patients with multi-system organ failure
at baseline, so the trajectory of organ dysfunction mat-
tered much more than the baseline severity of disease
because the blue group, even with multi-system organ
dysfunction, had improved outcomes.
(20) And so, just to summarize, we found that non-
pulmonary organ dysfunction is important for COVID-
19, and that additive non-improving organ failure
drives outcomes. This has us thinking—now that we’re
in the era of standard dexamethasone treatment, which
we were not in the Springtime—in the face of addi-
tive or non-improving organ dysfunction, what are the
next steps for immunomodulation? Because it seems
that this is not an ongoing viral-driven process, but
dysregulated immune response. Some patients are re-
fractory to corticosteroid therapy, meaning that they
have progressive organ dysfunction that is not fully ad-
dressed by corticosteroid therapy; some of these ad-
ditive or new organ dysfunctions, unfortunately, are
ICU-acquired problems like secondary infections and
thromboembolic disease events. So it’s not just a dys-
regulated immune response, but this is kind of where
the next stage is, as far as I can tell.
DR. NIEDERMAN
(21) Right, and Ed has also done some really interest-
ing work on mechanical ventilation. One of the con-
troversies has been whether the ARDS of COVID is the
same or different from traditional ARDS. Some people
have observed that the lung compliance in some of the
COVID patients was not as low as in traditional ARDS.
In Ed’s study of the ICU patients, lung compliance re-
ally was pretty much the same as ARDS, but some peo-
ple speculated that patients who had respiratory failure
with more normal lung compliance were primarily sick
because of pulmonary vascular disease. We know that
these patients did have microthrombi. There was, of
course, a lot of interest in anti-inflammatory therapy, in
addition to dexamethasone using anti-IL-1, treatments
like anakinra, IL-6, tocilizumab, using JAK inhibitors
like baricitinib, and all this has been really interesting.
There’s been a number of novel therapies that we have
not been involved with; for example, there was a study
primarily conducted in Florida looking at Ivermectin
because of its potential antiviral and viral binding ef-
fects and mediator effects. So there’s a lot of thera-
pies, but I think we stuck to pretty traditional therapy,
and as Ed mentioned, corticosteroids have really estab-
lished a key role for inpatients who need oxygen. As
you know, in the recovery trial, the benefit of steroids
was not present for those who did not need oxygen. We
use a lot of remdesivir, and there’s been interest in other
clinical trials of anti-inflammatory therapy, but nothing
has been established in the mainstream for all patients
right now. Ed, do you want to say anything else about
our clinical trials?
DR. SCHENCK
(22) Yeah, so our current clinical trial framework is in
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Figure 2. Distinct worsening and recovering subphenotypes.[9]
Figure 3. Trajectory predicts outcomes. WA=worsening subphenotype alive; RA=recovering subphenotype alive; WE=worsening subphenotype
extubated; RE=recovering subphenotype extubated.[9]
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the background of dexamethasone and remdisivir as
the standard of care. With our moderate and severe
patients, we are participating in the NIH’s ACTIV-1
platform trial, which is studying a combined bucket
of anti-inflammmatories, from infliximab to CCR5 in-
hibitors and CTLA-4 inhibitor (I think is the third one).
And in addition to that, we have a convalescent plasma
trial called CONCOR-1, which is wrapping up in the
near future, an anti-thrombotic trial that is investigator-
initiated, and a phase one cellular therapy trial in an
early phase that’s investigator-initiated. We’re also
opening up an anakinra study for the pre–mechanical
ventilation piece. We’re trying now to hit the different
immunomodulatory pathways, thrombotic pathways,
and other pathways as patients progress.
DR. NIEDERMAN
(23) Yeah, but I think it’s really important to empha-
size that all of these preliminary data and mechanisms
are still trials, and they’re not the standard of care for
everybody. And I think that in your own institution,
it’s really important that you participate in organized
data collection and clinical trials, rather than, say, you
read a paper that looked good; now you’re going to
change the way you practice for everybody—I don’t
think that’s really the way we ought to be doing things.
So we certainly have learned a lot, and I think the ra-
pidity with which these trials got done in the ICU is
another very important lesson that we’ve learned dur-
ing COVID that we hope will carry over moving for-
ward. Particularly, also, the multidisciplinary nature of
these studies—cooperation between cardiology, critical
care, neurology, particularly infectious diseases, even
rheumatology and hematology—has been very impres-
sive during this time, and I think it’s, again, established
a new paradigm that we can use going forward.
(24) I just want to finish up the review of how COVID
has changed things by talking a little bit about what im-
pact it’s had on our medical education experiences, and
I don’t think we’re unique in this. Like this conference,
almost all our conferences are now being done by inter-
net. A lot of us who used to drive ourselves crazy, run-
ning through airports and traveling all over the world
are asking ourselves, “gee, do we really need to keep
doing that?” I mean, it may be interesting; it may be
fun, but it’s certainly not as necessary as we thought.
We’ve had some very effective educational experiences
via the internet, in our training programs, both in inter-
nal medicine and in pulmonary critical care. Prospec-
tive trainees have been interviewed by Zoom; they’re
not making site visits anymore. One of the things that
I’ve wondered about, and I don’t think there’s a good
answer, is when people watch what we do, has that in-
creased or decreased the appeal of critical care as a spe-
cialty? I think on the one hand, it looks really exciting,
and it’s really nice to be at the cutting edge of medicine.
On the other hand, looking at some of my colleagues,
and the exhaustion and the emotional stress of working
with these patients, and the incredible hours they’ve
had to work—that may not be an appealing model to
all trainees.
(25) I think that one of the lessons we’ve all been
aware of is that we need to focus on the work-life bal-
ance, family life, and the emotional stress of working in
the ICU. This has been an ongoing crisis in the hospital,
and in particular for critical care doctors. And I think
that, although we were aware of this always, COVID
has made us even more aware of the importance of hav-
ing some sort of plan for emotional stress relief and try-
ing to deal with wellness in the physicians and the care
team who take care of COVID. So, I would just con-
clude the formal part of this presentation by saying that
we’ve learned a lot during COVID; I think it’s changed
the way we practice, but I think a lot of this will carry
over going forward. And I think for us, it’s been an ex-
hausting time, but it’s also been a very exciting time,
particularly when you have someone like Ed summa-
rize all the activities we’ve been involved with and all
the progress that’s been made in what has really been
a remarkably short time—less than a year. So I think
this has been one of the most exhausting and yet exhil-
arating times in our specialty, and I hope that some of
that’s come across and we were able to share some of
those ideas with you today. Julio?
DR. RAMIREZ
(26) Excellent—I think that’s a lot of lessons learned
that you just compacted into 30 minutes. And now,
the second part of this conversation is how do we
see COVID-19 in 2021. For instance, what’s going to
happen with therapy; when are we going to get new
therapies? You already mentioned the post-COVID
clinic they’re developing in almost every place—how
are we going to deal with these patients and what do
we think is going to happen there? There are all these
COVID barriers emerging in all these places around the
world; what’s going to happen with monoclonal anti-
body plasma, and of course, the critical issue, what’s
going to happen with vaccines? Of course, there is no
clear data, but I would like to throw some of these con-
cepts to both of you and ask how you see some of these
areas for 2021?
DR. NIEDERMAN
(27) Well, I hope the biggest thing that’s going to hap-
pen in 2021 is we’re going to be seeing COVID in the
rearview mirror. I’m really hoping that with vaccina-
tion, we’re going to be finally turning a corner here,
seeing less and less of this. That hasn’t really happened
yet, and I think we’re all worried that for some of the
reasons you said, maybe it will, and maybe it won’t, but
I think certainly it’s something that we’ve all been look-
ing forward to. What I anticipate is a lot of refinements
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in what we do because I think the studies that are be-
ing done now, compared to the studies that were done
a year ago, are much better controlled; the populations
are better defined, and the timing of the intervention is
more specific. There’s a number of examples of clini-
cal data that are positive now for therapy that weren’t
positive in the past: convalescent antibodies are a good
example; early studies on tocilizumab were negative—
some new ones are positive. So I think we’re probably
going to learn a little better when to apply these thera-
pies in which specific populations, whereas I think ear-
lier studies were broad strokes just trying to see if any-
thing worked. I think that that was an effective strategy
because it certainly cemented for us the value of corti-
costeroids, which were controversial as a treatment for
viral infection prior to COVID. So I see it as a focusing
down; I’m not sure what other therapies will emerge,
but as Ed said, in our hospital, we’re still sticking to the
basics while we add on other therapies to see whether
we can improve outcomes and define subsets that need
those therapies. Ed, what are your thoughts?
DR. SCHENCK
(28) So, in terms of the rearview mirror for COVID,
that’s what I’m hoping for. If you look at the nat-
ural history of respiratory viruses’ relationship with
humanity—flu being an outlier, but using other coro-
naviruses as a model—antigenic drift does not really
lead to sustained severity of illness. There’s a beautiful
paper in Science, published last week, that’s a model-
ing study comparing the natural exposure history of
other kinds of coronaviruses in the course of a pop-
ulation. Basically, about 90% of the population is in-
fected by the time they’re 4 or 5 years old, and reinfec-
tions are common but associated with minimal symp-
toms. So, even with the setting of antigenic drift, in
terms of what’s happening with the spike protein with
all of these variants, viruses are not out there to kill
us; they’re out there to reproduce—the goal of a virus
is just to continue its own genome. So, the selective
pressures for the relationship with our immune sys-
tem are probably such that it will evolve to a point
where it can bounce from host to host happily over the
course of a lifetime, producing symptoms that enable
it to bounce—meaning cough and cold-like symptoms
through which to propagate itself—but potentially our
immune system, in terms of limiting collateral dam-
age and organ dysfunction, will reach a steady state.
So I think that if you look at other coronaviruses as
an example, or if you look at other respiratory viruses,
the most likely long-term outcome is that this will be-
come endemic and that we will be looking at the se-
vere COVID respiratory failure, as Mike said, in the
rearview mirror.
(29) However, in terms of what lessons we learned
about trials and how to adapt therapies quickly and ex-
pand critical care to large, unanticipated populations, I
think those are going to be so important because there
will potentially be another coronavirus or a different
strain of the flu or an as yet unknown respiratory virus.
Using adaptive platform trials as a new standard to
test multiple therapies in large populations and what
the NIH is doing with the ACTIV platform trials—
hopefully, this will not be in our rearview mirror any-
time soon. Hopefully, this will be the standard, and
we’ll be able to define diseases better; we’ll stop call-
ing things traditional ARDS—we’ll call it viral ARDS
or coronavirus ARDS or flu ARDS or staph pneumo-
nia. And we’ll have adaptive platform trials for those
specific sources of respiratory failure, as opposed to
these nonspecific syndromes, learning as we go along
for specific diseases. That’s what I hope the research
community takes away as a real positive from this pan-
demic experience.
DR. NIEDERMAN
(30) I think that’s a great perspective. I do want to say
one more thing about vaccines. I think we’re all pretty
hopeful about the vaccines and what they’re going to
do for this disease, but I think we’ve got to be a little
bit circumspect until we learn a little more. I’m begin-
ning to read articles that say, “as soon as you’re two
weeks post your second vaccination, throw away your
mask, go hug your kids, go visit your friends, and start
going out to dinner.” We don’t know that yet. And
I think we’ve got to be really careful before we over-
estimate the potential of the vaccines and be sure that
we’re not spreading the disease or creating other prob-
lems. I think we’ve got to get there slowly. Today is
two weeks after my second dose, but I haven’t thrown
away my mask yet, and I think I’m probably going to
be very cautious until I begin to see the frequency of the
disease decline, hospital beds being open, and hospi-
tal and ICU capacity being closer to normal because in
the rare event that the vaccine doesn’t protect you, you
want to be treated in an environment that’s prepared to
take care of you.
DR. RAMIREZ
(31) You mentioned, Ed, that you started to
prioritize—you made a ranking of the clinical trials—
and I think that happened with COVID-19 in almost all
universities. Until now, everybody had their own area
to treat and you were selected as an investigator based
on your area, but with COVID-19, as you said, all the
companies—even the NIH—were looking at multiple
investigators, and at a lot of universities, the ID physi-
cians, pulmonary physicians, critical care physicians,
anesthesiologists, and even rheumatologists were all
doing critical tasks. How did you develop the system
to make sense of these 75 studies with everybody look-
ing at the same type of patient?
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Figure 4. Recorded vs. real COVID-19 case numbers in the United States. Recorded data (blue) from Financial Times (https://ig.ft.com/
coronavirus-chart/); modeled actual cases (red) from Dr. Schenck’s as yet unpublished research, kindly provided by the author.
DR. SCHENCK
(32) So we had this steering committee set up with
members from various disciplines—ID was a strong
presence; I was a representative for pulmonary criti-
cal care; we also had representatives from rheumatol-
ogy, general internal medicine, hematology, and on-
cology because of their prior clinical trials experience
and because some of the molecules were actually from
their area. As new protocols would come in, a mem-
ber of the task force was charged with reviewing that
protocol, evaluating it, and then presenting it to the
rest of the group, with the overarching guidance that
the 2 things we wanted to stress primarily were large,
well-funded phase III studies with a mechanism that
our group was enthusiastic about, and then also bear-
ing mind what was already approved. So, if it was
approved once already, it would preclude other com-
peting studies within the same timing, framework, or
mechanism. Sometimes the timing mattered, and we
also wanted to make sure that our studies included dif-
ferent phases of the disease treatment: the outpatient
phase, early moderate inpatient phase, and the severe
phase. The other responsibility of the steering commit-
tee was to weight our own investigators; if they had a
good idea, something that could lead towards institu-
tional advancement, then we would weight that simi-
larly to a large phase III study.
DR. NIEDERMAN
(33) And they did a great job; the principle that was
followed was not only providing for patient needs, but
really good science. They resisted the temptation to to
make the studies servants of individual investigators
and made the choices for the greater good of the pa-
tients in the community.
DR. RAMIREZ
(34) Very good! And you both mentioned that dur-
ing the second surge, there have been fewer patients in
the hospital and fewer patients in the ICU. This is hap-
pening globally; why is it that there are more cases of
COVID, but fewer patients in the ICU?
DR. NIEDERMAN
(35) I don’t know the answer; I would like to believe
that we’ve learned how to better manage these patients.
I can tell you that my view has changed 180 degrees.
I was involved in an NIH workshop probably 15 or
20 years ago about the original SARS epidemic, and
what had come out was that 20% of all the people who
got SARS were health care workers, primarily inten-
sivists and respiratory therapists, because they were in-
tubating patients late, they didn’t have the opportunity
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to use quite as much protective equipment, and they
were often contaminated during the intubation pro-
cess. One of the conclusions, then, was that if a patient
has any borderline respiratory failure, you should intu-
bate them early rather than wait and be in an emergent
situation that would be a great risk to the staff. But
we’ve completely changed that view, and we’ve cer-
tainly realized that some of the early gung-ho intuba-
tions were probably not necessary and may have actu-
ally contributed to some of the long-term ventilation.
The more widespread use of corticosteroids and rem-
disivir probably had a positive impact. I would hesi-
tate to say that the virus has become less virulent. But
I think we’re all grateful for the fact that the ICUs, al-
though they’re certainly stressed, aren’t stressed to the
extent that they were in the Spring. On the other hand,
I’m just speaking from our experience here in New
York; when you look at news reports, what’s happen-
ing in southern California, for example, doesn’t seem
like what we’re seeing here.
DR. SCHENCK
(36) I have another slide here that addresses this ques-
tion to some extent (Figure 4). The testing dynamic has
completely changed our perception of the case num-
bers, so this is a curve across the United States, and
you can see a shallow hump in March and April, but
in order to get tested in March and April, you had to
be nearly critically ill, coming into the emergency de-
partment and destined to be admitted to the hospital.
If you weren’t sick enough to be admitted to the hos-
pital, you didn’t get a COVID test, so the actual case
number was potentially miscounted by a factor of 10 to
20 in the hardest-hit cities in March and April. So the
idea that the dynamic has changed so much could actu-
ally just be an artifact of testing, that we’re picking up
minimally-to-asymptomatic cases now that we weren’t
detecting at all in the early part of the surge. Addi-
tionally, for hospital-related outcomes, there’s emerg-
ing evidence that inpatient mortality is completely de-
pendent on the amount of community spread; there are
some preprints circulating right now. The amount of
hospital strain—meaning the choice to admit patients
or not because of how many patients are already in the
hospital—is actually a key determinant of what your
inpatient mortality looks like. So, if you have the lux-
ury of being able to admit patients who are less severe,
your inpatient numbers and ICU numbers are going to
look better. So, if you have a low community burden of
disease, you’re identifying cases in real time, and you
have a hospital that’s not burdened, you can admit a
patient, give them a few days of oxygen, a few days of
dexamethasone, and send them home, whereas if they
were left at home, they probably would have done OK
as well. But that makes it look like your inpatient num-
bers and treatment strategies have really made a differ-
ence.
DR. NIEDERMAN
(37) The only thing about that is, at least in our hos-
pital, in spite of the liberalized use of the hospital in
the diagnoses, we actually have a total number of inpa-
tients much lower than we had in the Spring, so some-
thing has changed.
DR. SCHENCK
(38) Yeah, but I think it’s related to the actual numbers
within the community.
DR. NIEDERMAN
(39) Alright, Julio, thank you so much.
DR. RAMIREZ
(40) It was a pleasure; thank you, both of you. We’ll
keep in contact. I’m sure that the audience is going to
enjoy your presentation and your insight into COVID
last year and COVID this year.
DR. NIEDERMAN
(41) And of course, the other exciting thing about this
is that we’ve had young investigators like Ed who’ve
really come into their own in this crisis, so it’s a very
exciting time indeed.
DR. RAMIREZ
(42) Thank you, both of you.
DR. NIEDERMAN
(43) Thanks a lot.
DR. SCHENCK
(44) Take care.
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